Carmell Therapeutics to go public via $328m SPAC deal with Alpha Healthcare
Carmell Therapeutics, a phase 2-stage biotechnology platform company, is set to go public through a merger deal with Alpha Healthcare Acquisition Corp. III, a special ... Read More
Carmell Therapeutics gets IND clearance for CT-101 bone healing accelerant
Carmell Therapeutics has secured clearance from the US Food and Drug Administration (FDA) for its investigational new drug application (IND) for CT-101, its first product, ... Read More